-+ 0.00%
-+ 0.00%
-+ 0.00%
Xanadu Quantum Technologies (TSX:XNDU) Lands A Bluefors Partnership, Is The Stock Still Overvalued?
Share
Listen to the news

Xanadu Quantum Technologies (TSX:XNDU) moved into focus after announcing a multi million dollar partnership with Bluefors to build a cryogenic prototype for utility scale quantum computing data centres.

Despite the Bluefors agreement, Xanadu Quantum Technologies is still working through a tough patch, with the share price return down 55.0% year to date and 54.6% over 90 days, even after an 11.8% one-day jump that hints at short term momentum picking up while the longer term trend remains weak.

Scan beyond Xanadu Quantum Technologies and see how other quantum and AI infrastructure players are setting up with the 91 AI infrastructure stocks in today’s market narrative.

The recent 11.8% jump only scratches the surface of Xanadu Quantum Technologies’ year to date decline. Is this where most of the recovery is already priced in, or is this the point at which the potential reward is only starting to be tested?

Preferred Price-to-Book of 4.9x for Xanadu Quantum Technologies: Is it justified?

At a last close of CA$7.21, Xanadu Quantum Technologies is trading on a P/B of 4.9x, which screens as expensive next to both the Canadian software sector average of 3.4x and its closer peer set on 3.2x.

P/B compares the market value of the equity to the accounting value of net assets. For a business like Xanadu Quantum Technologies, which is still loss making and focused on building out quantum hardware and software platforms, investors often lean on this yardstick because earnings are not yet a clean guide.

The current premium suggests the market is paying a higher price for each dollar of book equity than it does for many Canadian software peers. With revenue of CA$7.205m and a reported net loss of CA$105.977m, the valuation multiple indicates that investors may be focusing on the quantum computing opportunity rather than present losses. At the same time, the negative return on equity of 33.85% and ongoing unprofitability highlight execution and financing risk that may not be fully reflected in a higher than average P/B.

Relative to both the 3.4x wider industry level and the 3.2x peer group figure, the 4.9x P/B for Xanadu Quantum Technologies places the stock at the more expensive end of the range. This means the market is assigning a premium that other software companies with more seasoned management teams or more established profitability do not currently command.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 4.9x (OVERVALUED)

Still, the story around Xanadu Quantum Technologies can be knocked off course if funding costs rise sharply or large partners rethink long term commitments.

Find out about the key risks to this Xanadu Quantum Technologies narrative.

Next Steps

Mixed signals around Xanadu Quantum Technologies can feel confusing, so move quickly, review the facts for yourself, and weigh both the risks and rewards in the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Xanadu Quantum Technologies?

If Xanadu Quantum Technologies has sharpened your focus on valuation and risk, you may want to broaden your watchlist by scanning other opportunities with stronger income, quality and resilience profiles.

  • Target reliable cash payouts and steady income streams by reviewing the 1 dividend fortresses that could complement a growth focused position like Xanadu Quantum Technologies.
  • Spot potential value opportunities before sentiment shifts by working through the 7 high quality undervalued stocks that combine solid fundamentals with pricing that still looks compressed.
  • Prioritise capital preservation by filtering for the 8 resilient stocks with low risk scores that aim to balance upside potential with tighter risk controls.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending